k 2025

Aniline Derivatives as Potent Carbonic Anhydrase Inhibitors

ŠELIGOVÁ, Karolína; Eva HAVRÁNKOVÁ a Jozef CSÖLLEI

Základní údaje

Originální název

Aniline Derivatives as Potent Carbonic Anhydrase Inhibitors

Autoři

Vydání

53rd Conference Synthesis and Analysis of Drugs 2025, 2025

Další údaje

Jazyk

angličtina

Typ výsledku

Prezentace na konferencích

Obor

30104 Pharmacology and pharmacy

Utajení

není předmětem státního či obchodního tajemství

Označené pro přenos do RIV

Ano

Organizační jednotka

Farmaceutická fakulta

ISBN

978-80-280-0773-7

Klíčová slova anglicky

carbonic anhydrase inhibition; triazine; benzenesulfonamide; aniline
Změněno: 18. 11. 2025 11:04, PharmDr. Karolína Šeligová

Anotace

V originále

Carbonic anhydrases are omnipresent metalloenzymes that catalyze reversible conversion of carbon dioxide to bicarbonate and proton, maintaining homeostasis. In humans, they are involved in multiple physiological processes, and they are linked to many disorders, such as glaucoma, neurodegeneration or cancer. Their potential inhibition is of considerable interest in biomedical research. [1]. In bacteria, inhibition of carbonic anhydrases leads to inhibition of their growth and makes them more vulnerable to host defense mechanisms [2]. Based on our previous findings, where a lead 1,3,5-triazinyl aminobenzenesulfonamide incorporating an aniline motif exhibited high inhibitory activity against carbonic anhydrase (Kᵢ = 7.4 nM against CA IX ), we designed and synthesized a series of related derivatives to further explore structure–activity relationships and improve selectivity. The new compounds were evaluated for their inhibitory activity against various CA isoforms.

Návaznosti

MUNI/A/1474/2024, interní kód MU
Název: Syntéza selektivních inhibitorů bakteriálních karboanhydráz
Investor: Masarykova univerzita, Syntéza selektivních inhibitorů bakteriálních karboanhydráz
MUNI/G/1002/2021, interní kód MU
Název: Insight into CAIX structure and function and design of selective inhibitors as potential anti-cancer drugs (Akronym: CAIX-target)
Investor: Masarykova univerzita, Insight into CAIX structure and function and design of selective inhibitors as potential anti-cancer drugs, INTERDISCIPLINARY - Mezioborové výzkumné projekty